![Stefan Norin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 2 740 $ al 31/05/2026
Stefan Norin currently works at Oncopeptides AB, as Chief Medical Officer from 2023.
Mr. Norin also formerly worked at Medivir AB, as Associate Director-Clinical Research & development from 2017 to 2019 and Karolinska University Hospital, as Head-Lymphosection.
Mr. Norin received his doctorate degree from Karolinska Institutet.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 19/03/2026 | 13.975 ( 0 % ) | 2 740 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| ONCOPEPTIDES AB | Director Técnico/Científico/I+D | 01/09/2023 |
| Empresas | Cargo | Fin |
|---|---|---|
| MEDIVIR AB | Director Técnico/Científico/I+D | 01/03/2019 |
Karolinska University Hospital
 Karolinska University Hospital Hospital/Nursing ManagementHealth Services Provides hospital services | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Medivir AB
 Medivir AB Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Karolinska Institutet
 Karolinska Institutet Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Oncopeptides AB
 Oncopeptides AB Pharmaceuticals: MajorHealth Technology Develops chemotherapeutic pharmaceuticals of compounds for cancer treatment | Health Technology |
Karolinska University Hospital
Karolinska University Hospital Hospital/Nursing ManagementHealth Services Provides hospital services | Health Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
